SNT · ASX

Syntara Limited (ASX:SNT)

AU$0.054

 0.003 (5.882%)
ASX:Live
17/07/2025 04:10:00 PM
Hammer Bullish HALO Ords HALO Consensus Value GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

SNT Overview

SNT Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About SNT

Website

Syntara Limited

Telephone

61.2.9454.7200

Address

Frenchs Forest 20 Rodborough Road Sydney, New South Wales (NSW) 2086

Description

Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.

SNT Price Chart

Key Stats

Market Cap

AU$79.67M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.09

Trade Value (12mth)

AU$78,804.00

1 week

2%

1 month

-12.07%

YTD

-35.44%

1 year

27.5%

All time high

4.31

Key Fundamentals

EPS 3 yr Growth

200.00%

EBITDA Margin

N/A

Operating Cashflow

-$14m

Free Cash Flow Return

-202.20%

ROIC

-190.80%

Interest Coverage

-47.80

Quick Ratio

1.80

Other Data

Shares on Issue (Fully Dilluted)

1509m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

SNT Announcements

Latest Announcements

Date Announcements

15 July 25

First patient dosed in SATELLITE Phase 1c for keloid scars

×

First patient dosed in SATELLITE Phase 1c for keloid scars

08 July 25

WHO grants official INN for SNT-5505 - amsulostat

×

WHO grants official INN for SNT-5505 - amsulostat

02 July 25

Notification regarding unquoted securities - SNT

×

Notification regarding unquoted securities - SNT

02 July 25

Proposed issue of securities to the CEO

×

Proposed issue of securities to the CEO

01 July 25

Application for quotation of securities - SNT

×

Application for quotation of securities - SNT

23 June 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

16 June 25

Application for quotation of securities - SNT

×

Application for quotation of securities - SNT

13 June 25

SNT-5505 interim Phase 2 data webinar

×

SNT-5505 interim Phase 2 data webinar

13 June 25

New positive interim data in Phase 2 study of SNT-5505

×

New positive interim data in Phase 2 study of SNT-5505

13 June 25

EHA 2025 SNT-5505 Interim Data Webinar Presentation

×

EHA 2025 SNT-5505 Interim Data Webinar Presentation

10 June 25

SNT-5505 awarded US FDA Fast Track designation

×

SNT-5505 awarded US FDA Fast Track designation

10 June 25

Application for quotation of securities - SNT

×

Application for quotation of securities - SNT

26 May 25

Change in substantial holding

×

Change in substantial holding

22 May 25

Change in substantial holding

×

Change in substantial holding

07 May 25

Investor Presentation

×

Investor Presentation

01 May 25

March Quarter Shareholder Update Presentation

×

March Quarter Shareholder Update Presentation

30 April 25

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

30 April 25

Quarterly Activities Report

×

Quarterly Activities Report

30 April 25

Appendix 4C quarterly webinar

×

Appendix 4C quarterly webinar

29 April 25

Updated SNT-5505 study data to be presented at EHA2025

×

Updated SNT-5505 study data to be presented at EHA2025

24 April 25

Change in substantial holding

×

Change in substantial holding

31 March 25

Change in substantial holding

×

Change in substantial holding

28 March 25

Application for quotation of securities - SNT

×

Application for quotation of securities - SNT

28 March 25

Notification of cessation of securities - SNT

×

Notification of cessation of securities - SNT

24 March 25

Change in substantial holding

×

Change in substantial holding

SNT Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.02 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.02 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 53.4 -408.8 -26.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -830.6 46.1 -25.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -44.2 -23.1 -63.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 365.7 -30.7 -69.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 563 656 955 Lock Lock Lock
Basic m Lock Lock Lock Lock 563 656 955 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 10 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -56.9 -100.0 N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 13 18 18 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -7 -2 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -191.4 72.0 87.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -67.5 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 168 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -17 -18 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -1,234.7 -7.9 -2.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -170.7 N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 3 2 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -20 -20 -19 Lock Lock Lock
     Growth % Lock Lock Lock Lock -352.4 0.4 5.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -203.9 N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -19 -18 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -5 -5 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -11 -21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 34.8 -486.8 -84.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -19.8 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -16 -7 -14 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 7 7 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -16 -7 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -690.1 54.1 -95.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.7 N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 9 9 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 25 24 10 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 6 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -5 -1 -3 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 14 14 6 Lock Lock Lock
Equity $m Lock Lock Lock Lock 11 10 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 13 16 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 83.1 21.5 -70.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -7.7 -47.3 -201.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.9 -118.8 -447.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -164.1 -120.2 -220.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -19.2 -92.8 -190.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -159.4 -50.3 -202.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A -80.7 -47.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.3 0.0 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -43.0 -9.1 -60.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.2 2.3 1.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.8 2.1 1.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 46.5 49.4 36.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -264.0 -90.6 -265.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 1.9 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 5.5 0.9 0.3 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.7 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 6.3 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -70.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -27.1 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -7.7 -47.3 -201.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.3 2.5 2.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.9 -118.8 -447.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -17.9 -118.8 -447.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 66.7 392.8 1,290.9 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 193.9 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 260.6 392.8 1,290.9 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 22.5 217.0 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 238.1 175.9 1,290.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

SNT Shortsell

Frequently Asked Questions

The current share price of Syntara Limited (SNT:ASX) is AU$0.054.
The 52-week high share price for Syntara Limited (SNT:ASX) is AU$0.09.
The 52-week low share price for Syntara Limited (SNT:ASX)? is AU$0.03.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) has a franking level of 0.0%.
Syntara Limited (SNT:ASX) is classified in the Healthcare.
The current P/E ratio for Syntara Limited (SNT:ASX) is .
The current share price of Syntara Limited (SNT:ASX) is AU$0.054.
The 52-week high share price for Syntara Limited (SNT:ASX) is AU$0.09.
The 52-week low share price for Syntara Limited (SNT:ASX)? is AU$0.03.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) has a franking level of 0.0%.
Syntara Limited (SNT:ASX) is classified in the Healthcare.
The current P/E ratio for Syntara Limited (SNT:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.